Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.4100 (-1.64%) ($5.2900 - $5.5400) on Wed. Oct. 3, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.48% (three month average) | RSI | 16 | Latest Price | $5.4100(-1.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -24.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SHY(6%) XHB(6%) DIA(5%) TLT(5%) IPO(4%) | Factors Impacting TGTX price | TGTX will decline at least -3.24% in a week (0% probabilities). XLC(-8%) URA(-8%) XLRE(-6%) UNG(-6%) SIL(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.24% (StdDev 6.48%) | Hourly BBV | 0 () | Intraday Trend | -0.4% | | | |
|
1 - 5 Day Possible Target | $-39.7(-833.83%) | Resistance Level | $8.47 | 5 Day Moving Average | $5.54(-2.35%) | 10 Day Moving Average | $6.46(-16.25%) | 20 Day Moving Average | $8.47(-36.13%) | To recent high | -61.4% | To recent low | 5% | Market Cap | $685m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |